>95^%

97^%

National commercial and Medicare Part D formulary coverage under the pharmacy benefit as of May 2023.²

*SKYRIZI is on a preferred tier or otherwise has preferred status on the plan’s formulary.

^†Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

If you have determined that SKYRIZI is the appropriate treatment, preferred* access could mean:

EXCEPTIONAL access

for commercial patients

Standard PRIOR AUTHORIZATION (PA) and appeal processes

potential for one-time PA/appeal approval

GET YOUR PATIENTS STARTED

PLANS LISTING SKYRIZI AS PREFERRED FOR Ps IN YOUR COUNTY

See which plans in your area include SKYRIZI on their preferred drug Formulary

Select a filter

Please enter a valid zip code.

Coverage requirements and benefits designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies. The health plans and/or pharmacy benefit managers listed here have not endorsed and are not affiliated with this material.

Local can include national, regional, state, State Medicaid, and Managed Medicaid plans within the given geography.

BRIDGE PROGRAM ELIGIBILITY

Product available for eligible, commercially insured patients during the appeal process due to step therapy requirement^‡

SKYRIZI® is the #1 prescribed biologic by dermatologists for patients with psoriatic disease.

#1 PRESCRIPTION ANALYSIS CALCULATED BY COMBINED PRESCRIPTION DATA ACROSS Ps AND PsA

For patients with psoriatic disease, defined as those with plaque psoriasis or psoriatic arthritis. Source of data: Integrated Symphony Health (PatientSource) as of 3/2023.³

Encourage your patients to enroll in

AFFORDABILITY

Commercially insured patients may pay as little as $5 per quarterly dose^§

One-to-one support

Nurse Ambassadors^‖

Access

No charge for eligible patients experiencing initial insurance denial^‡

^‡Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI® (risankizumab-rzaa) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI® (risankizumab-rzaa) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

^§Terms and Conditions apply. This benefit covers SKYRIZI® (risankizumab-rzaa). Eligibility: Available to patients with commercial insurance coverage for SKYRIZI® (risankizumab-rzaa) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit SKYRIZISavingsCard.com or call 1.866.SKYRIZI for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy

^‖Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing health care professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

Stay up to date on the latest SKYRIZI news and information